The VEGF family in cancer and antibody-based strategies for their inhibition

Laura A. Sullivan, Rolf A. Brekken

Research output: Contribution to journalArticle

103 Citations (Scopus)

Abstract

Angiogenesis is required in normal physiological processes, but is also involved in tumor growth, progression and metastasis. Vascular endothelial growth factor (VEGF), a primary mediator of angiogenesis in normal physiology and in disease, and other VEGF family members and their receptors provide targets that have been explored extensively for cancer therapy. Small molecule inhibitors and antibody/protein-based strategies that target the VEGF pathway have been studied in multiple types of cancer. This review will focus on VEGF pathway targeting antibodies that are currently being evaluated in preclinical and clinical studies.

Original languageEnglish (US)
Pages (from-to)165-175
Number of pages11
JournalmAbs
Volume2
Issue number2
DOIs
StatePublished - Mar 2010

Fingerprint

Vascular Endothelial Growth Factor A
Antibodies
Neoplasms
Physiological Phenomena
Neoplasm Metastasis
Inhibition (Psychology)
Growth
Proteins
Therapeutics

Keywords

  • Antibodies
  • Cancer therapy
  • VEGF
  • VEGF receptors

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

The VEGF family in cancer and antibody-based strategies for their inhibition. / Sullivan, Laura A.; Brekken, Rolf A.

In: mAbs, Vol. 2, No. 2, 03.2010, p. 165-175.

Research output: Contribution to journalArticle

@article{64fd39fb36c5471b8cfd5b04c3c04dd3,
title = "The VEGF family in cancer and antibody-based strategies for their inhibition",
abstract = "Angiogenesis is required in normal physiological processes, but is also involved in tumor growth, progression and metastasis. Vascular endothelial growth factor (VEGF), a primary mediator of angiogenesis in normal physiology and in disease, and other VEGF family members and their receptors provide targets that have been explored extensively for cancer therapy. Small molecule inhibitors and antibody/protein-based strategies that target the VEGF pathway have been studied in multiple types of cancer. This review will focus on VEGF pathway targeting antibodies that are currently being evaluated in preclinical and clinical studies.",
keywords = "Antibodies, Cancer therapy, VEGF, VEGF receptors",
author = "Sullivan, {Laura A.} and Brekken, {Rolf A.}",
year = "2010",
month = "3",
doi = "10.4161/mabs.2.2.11360",
language = "English (US)",
volume = "2",
pages = "165--175",
journal = "mAbs",
issn = "1942-0870",
publisher = "Landes Bioscience",
number = "2",

}

TY - JOUR

T1 - The VEGF family in cancer and antibody-based strategies for their inhibition

AU - Sullivan, Laura A.

AU - Brekken, Rolf A.

PY - 2010/3

Y1 - 2010/3

N2 - Angiogenesis is required in normal physiological processes, but is also involved in tumor growth, progression and metastasis. Vascular endothelial growth factor (VEGF), a primary mediator of angiogenesis in normal physiology and in disease, and other VEGF family members and their receptors provide targets that have been explored extensively for cancer therapy. Small molecule inhibitors and antibody/protein-based strategies that target the VEGF pathway have been studied in multiple types of cancer. This review will focus on VEGF pathway targeting antibodies that are currently being evaluated in preclinical and clinical studies.

AB - Angiogenesis is required in normal physiological processes, but is also involved in tumor growth, progression and metastasis. Vascular endothelial growth factor (VEGF), a primary mediator of angiogenesis in normal physiology and in disease, and other VEGF family members and their receptors provide targets that have been explored extensively for cancer therapy. Small molecule inhibitors and antibody/protein-based strategies that target the VEGF pathway have been studied in multiple types of cancer. This review will focus on VEGF pathway targeting antibodies that are currently being evaluated in preclinical and clinical studies.

KW - Antibodies

KW - Cancer therapy

KW - VEGF

KW - VEGF receptors

UR - http://www.scopus.com/inward/record.url?scp=77953666101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77953666101&partnerID=8YFLogxK

U2 - 10.4161/mabs.2.2.11360

DO - 10.4161/mabs.2.2.11360

M3 - Article

C2 - 20190566

AN - SCOPUS:77953666101

VL - 2

SP - 165

EP - 175

JO - mAbs

JF - mAbs

SN - 1942-0870

IS - 2

ER -